Analysts Anticipate Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Will Post Earnings of -$1.04 Per Share

Brokerages expect Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Rating) to report ($1.04) earnings per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Mirum Pharmaceuticals’ earnings. The highest EPS estimate is ($0.91) and the lowest is ($1.09). Mirum Pharmaceuticals posted earnings of ($1.45) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 28.3%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

On average, analysts expect that Mirum Pharmaceuticals will report full-year earnings of ($4.32) per share for the current financial year, with EPS estimates ranging from ($4.52) to ($4.02). For the next year, analysts expect that the business will post earnings of ($2.76) per share, with EPS estimates ranging from ($3.34) to ($1.53). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Mirum Pharmaceuticals.

Mirum Pharmaceuticals (NASDAQ:MIRMGet Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($1.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.39) by $0.22. Mirum Pharmaceuticals had a negative net margin of 218.74% and a negative return on equity of 163.01%. During the same quarter last year, the business posted ($1.68) earnings per share.

MIRM has been the subject of a number of research analyst reports. Zacks Investment Research lowered shares of Mirum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. SVB Leerink boosted their price target on shares of Mirum Pharmaceuticals from $50.00 to $52.00 and gave the company an “outperform” rating in a report on Tuesday. Raymond James boosted their price target on shares of Mirum Pharmaceuticals from $70.00 to $74.00 and gave the company a “strong-buy” rating in a report on Friday, March 11th. Finally, HC Wainwright boosted their price target on shares of Mirum Pharmaceuticals from $64.00 to $69.00 and gave the company a “buy” rating in a report on Monday. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $47.67.

MIRM traded up $0.18 on Friday, reaching $24.76. 307,578 shares of the company traded hands, compared to its average volume of 185,716. Mirum Pharmaceuticals has a one year low of $12.82 and a one year high of $28.65. The firm has a fifty day simple moving average of $24.48 and a two-hundred day simple moving average of $20.19. The company has a market cap of $788.23 million, a P/E ratio of -10.96 and a beta of 1.23.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its stake in shares of Mirum Pharmaceuticals by 5.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 15,500 shares of the company’s stock worth $342,000 after acquiring an additional 804 shares in the last quarter. Citigroup Inc. raised its stake in shares of Mirum Pharmaceuticals by 348.7% during the 4th quarter. Citigroup Inc. now owns 1,844 shares of the company’s stock worth $29,000 after acquiring an additional 1,433 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in shares of Mirum Pharmaceuticals by 6.6% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 25,322 shares of the company’s stock worth $404,000 after acquiring an additional 1,574 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Mirum Pharmaceuticals during the 1st quarter worth approximately $41,000. Finally, Geode Capital Management LLC raised its stake in shares of Mirum Pharmaceuticals by 1.4% during the 3rd quarter. Geode Capital Management LLC now owns 176,673 shares of the company’s stock worth $3,519,000 after acquiring an additional 2,402 shares in the last quarter. Hedge funds and other institutional investors own 87.68% of the company’s stock.

Mirum Pharmaceuticals Company Profile (Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

See Also

Get a free copy of the Zacks research report on Mirum Pharmaceuticals (MIRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.